Initial clinical trials with the nonselective BRAF inhibitor sorafenib produced dismal results, with clinical response rates of ≤5%.9 However, the treatment and outcomes of metastatic melanoma patients improved dramatically with the development of second-generation, mutation-specific BRAF inhibitors. Here, BRAF is linked to metastatic melanoma.